discovery of numerous additional AT-less type I PKSs incorporating variable extender units. However, biochemical characterization of AT-less type I PKSs remains very limited, and the mechanism by which AT-less type I PKSs accommodate multiple extender units is unknown. This chapter provides the protocols used to establish and characterize the LNM PKS. Application of these methods to other AT-less type I PKSs should aid the biochemical characterization and hence possible exploitation of these unique PKSs for polyketide natural product structural diversity by combinatorial biosynthetic methods.
Introduction
Polyketides constitute one of the largest families of natural products and many are biosynthesized by noniterative type I polyketide synthases (PKSs). Type I PKSs are multifunctional enzymes organized into modules, each of which harbors a set of distinct domains responsible for the catalysis of one cycle of polyketide chain elongation. Prototypically, a type I PKS elongation module contains minimally three domains-an acyltransferase (AT), an acyl carrier protein (ACP) and a b-ketoacyl synthase (KS)-that select, activate, and catalyze a decarboxylative Claisen condensation between the extender unit and the growing polyketide chain, generating a b-ketoacyl-S-ACP intermediate. Optional domains are found between the AT and ACP domains, which carry out the variable set of reductive modifications of the b-keto group before the ensuing cycle of chain extension (Shen, 2003; Staunton and Weissman, 2001) . For a prototypic type I PKS, as exemplified by the 6-deoxyerythromycin B synthase (DEBS) for biosynthesis of the aglycone of the polyketide antibacterial antibiotic erythromycin A (Donadio and Katz, 1992) , an AT domain is an integral part of every PKS module, and each AT domain functions only once, for the module in which it resides. Integral AT domains in such prototypic type I PKSs were thus termed cognate ATs (Cheng et al., 2003) (Fig. 8.1A) .
A distinct variant of the noniterative type I PKSs contains no cognate ATs but has a short segment of remnant AT sequence in some or all modules, depending on the pathway. This subclass of type I PKSs was named the AT-less type I PKSs and the remnant AT segment the AT docking domain (Fig. 8.1B and C) . The essential AT activities are provided in trans by discrete AT enzymes encoded by genes that are physically separated from the PKS genes. Therefore AT-less type I PKSs require discrete ATs acting in trans to select the extender unit and load it onto the ACP domain (Cheng et al., 2003) (Figs. 8.1C and 8.2) .
The AT-less class of type I PKSs was first discovered during genetic and biochemical studies of leinamycin (LNM) biosynthesis in Streptomyces atroolivaceus S-140 (Cheng et al., 2002; Cheng et al., 2003; Tang et al., 2004) .
LNM is a hybrid peptide-polyketide natural product that shows potent antitumor activity, most significantly against tumor cell lines that are resistant to clinically important anticancer drugs (Hara et al., 1989a,b) . The lnm biosynthetic gene cluster consists of multiple genes encoding modular nonribosomal peptide synthetases (NRPSs), type I PKSs, and other components. The most striking feature of LNM PKSs is the lack of cognate AT domains in all six modules of the LnmI and LnmJ PKS proteins; instead, only a segment of remnant AT sequence was found in five of the six PKS modules after each KS domain (Figs. 8.1C and 8.2) . Bioinformatic and genetic analyses identified lnmG as an essential AT-encoding gene, and biochemical studies subsequently confirmed LnmG as a discrete AT enzyme capable of loading the malonyl group from the extender unit substrate malonyl CoA onto the ACP domains in all six modules of the LnmI and LnmJ PKSs. On the basis of these findings, LnmI and LnmJ were hence proposed as the first AT-less type I PKSs, LnmG as the required trans-acting, discrete AT enzyme, and the remnant AT segments as AT docking domains (Figs. 8.1 and 8.2) . Numerous additional AT-less type I PKSs have since been discovered (Fig. 8.3 and Table 8 .1). However, unequivocal biochemical evidence validating this emerging subclass of AT-less type I PKSs remains scarce.
Noniterative type I PKSs use malonyl CoA, methylmalonyl CoA, ethylmalonyl CoA, methoxymalonyl ACP, and in rare cases, hydroxymalonyl ACP or aminomalonyl ACP, as extender units in the biosynthesis of diverse polyketide natural products (Chan et al., 2006; Khosla et al., 1999) . (See also Chapter 7 of this volume.) Biochemical studies (for LnmG) and substrate specificity predictions (for all others) suggest that most, if not all, discrete ATs known for AT-less type I PKSs use malonyl CoA as a substrate (Table 8.1 and Fig. 8.4 ). Possible exceptions to this finding include EtnB from the etnangien biosynthetic pathway (Menche et al., 2008) and KirCII from the kirromycin biosynthetic pathway (Weber et al., 2008) , which appear to AT-less type I PKS module lacks the cognate AT domain but often contains a short segment of remnant AT residues. (C) The remnant AT segment lacks critical catalytic motifs (GHSxG and AFHS) and is therefore catalytically inactive, but may serve as a docking domain mediating the interactions between the discrete AT (LnmG) and AT-less PKS modules in LnmI and LnmJ (Tang et al., 2004) . 
Figure 8.2 A model for LNM biosynthesis featuring the LNM hybrid NRPS-PKS megasynthetase with the discrete ATenzyme LnmG that loads the malonyl CoA extender units onto all six modules on the LnmI and LnmJ PKSs (Cheng et al., 2003; Tang et al., 2004) .
use succinyl CoA and ethylmalonyl CoA, respectively. An AT-less type I PKS that incorporates methoxymalonyl ACP as an extender unit has also been proposed, for the biosynthesis of oxazolomycin, the predicted discrete AT (OzmC) for which, however, shows little sequence homology to typical ATs known for PKSs. With the exception of LnmG, the actual substrate Figure 8 .3 Natural products whose biosynthetic pathways are predicted to feature AT-less type I PKSs.
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Pederin (Piel, 2002; Piel, et al., 2004a Piel, et al., , 2004b Piel, et al., , 2004c Piel, et al., , 2004d Piel, et al., , 2005 specificities for all discrete ATs identified for AT-less type I PKSs to date remain to be experimentally proven. This chapter describes protocols for biochemical characterization of AT-less type I PKSs, as previously applied to establish and characterize the LNM PKS. They include (1) heterologous expression and overproduction of ACPs from AT-less type I PKS modules; (2) in vitro preparation of Figure 8 .4 Phylogenetic analysis of cognate and discrete acyltransferases (ATs), highlighting substrate specificities. Phylogenetic analysis was performed by the neighborjoining method (Bruno et al., 2000) . Discrete ATs form a loose but distinctive clade distant from the cognate ATs of prototypical PKSs. For discrete ATs, see Table 8 .1 for references. For cognate ATs, NCBI accession numbers are given in parentheses.
holo-ACPs; (3) heterologous expression and overproduction of discrete ATs; (4) in vitro assay of AT substrate specificity; and (5) in vitro assay of AT-catalyzed loading of extender unit substrate onto holo-ACPs. The biochemical reactions examined are depicted in Fig. 8 .5.
Methods

Heterologous expression and overproduction
of apo-ACPs from AT-less PKS modules
1. Conduct sequence analysis (e.g., by ClustalW program [Thompson et al., 2002] ) to determine the boundaries of individual ACP domains from AT-less type I PKS modules (Donadio and Katz, 1992) . 2. Choose a host/vector system for heterologous gene expression [e.g., Escherichia coli BL21(DE3)/pET28a or pET37b from Novagen for overproduction of the gene product as His 6 -tagged fusion protein] and a subsequent protein purification system (e.g., by affinity chromatography on Ni-NTA resin from Qiagen). 3. Design and synthesize PCR primers for the amplification of DNA encoding the target ACP domains. Restriction sites (e.g., CATATG for NdeI and AAGCTT for HindIII) are routinely added to the primers to facilitate directional cloning. 4. Amplify the DNA by PCR with a high-fidelity DNA polymerase (e.g., Pfu Turbo DNA polymerase from Strategene), clone the amplicon into pET28a or pET37b, and sequence the construct to verify DNA amplification fidelity. 5. Introduce individual expression constructs into host strain E. coli BL21 (DE3) cells by transformation or electroporation. Select for transformants on LB agar supplemented with 25 mg/ml of kanamycin. 6. Optimize culture conditions on a small scale for overproduction of soluble ACPs by following the manufacturer's recommendations (e.g., the QIAexpressionist from Qiagen). 7. Scale up the culture volume for protein overproduction and proceed to purify sufficient amounts of individual ACPs for assays. We routinely grow 1 to 4 l of culture at 18 to 25 for 0.5 to 2 days and add 1 to 100 mM (final concentration) isopropyl b-D-1-thiogalactopyranoside (IPTG) to induce gene expression. We also routinely employ lysozyme and sonication to lyse cells, and use gravity Ni-NTA affinity chromatography and subsequently anion exchange FPLC (e.g., the Ä KTA system from Amersham Pharmacia) to obtain pure ACPs. 8. Examine protein fractions by SDS-PAGE and pool together the fractions with at least 95% purity. 9. Dialyze pooled protein samples against 25 mM Tris-HCl, pH 8.0, 25 mM NaCl, 2 mM DTT and 10% glycerol. 10. Re-examine the quality of the purified ACPs by SDS-PAGE ( Fig. 8.6A ), and determine their concentrations by Bradford assay (Bradford, 1976) . 11. Aliquot (e.g., 500 ml per 1.5-ml tube) and store the ACP samples at -80 until use.
In vitro preparation of holo-ACPs
PKS ACPs overproduced in E. coli under the conditions described above are generally in their nonphosphopantatheinylated apo-form. Apo-ACPs need to be converted into their functional holo-forms by attachment of the 4 0 -phosphopantetheine group from CoA to the active-site Ser residue. This post-translational modification of apo-ACPs to holo-ACPs can be carried out in vitro with promiscuous 4-phosphopantetheinyl transferases (PPTases) such as Svp (Fig. 8.5 ) and followed by HPLC, MS, or autoradiography analysis (Lambalot et al., 1996; Sanchez et al., 2001) .
In vitro preparation of holo-ACPs from apo-ACPs
1. Set up an analytical in vitro phosphopantetheinylation reaction in 100-ml volume as follows: (1) 25 ml of 4 X reaction buffer (400 mM TrisÁHCl, pH 7.5, 50 mM MgCl 2 , 10 mM DTT)l; (2) 10 ml of 2.5 mM CoA stock (final concentration 250 mM) (use 3 H-labeled CoA for autoradiography analysis); (3) 10 ml of apo-ACP (final concentration 10 mM ]; (4) 2 ml of Svp (final concentration 2 mM); and (5) add H 2 O to a total reaction volume of 100 ml. 2. Incubate the reaction at 25 for 30 to 60 min. 3. Add 900 ml of acetone to quench the reaction, and mix briefly by vortexing. 4. Freeze sample tube at -80 for at least 1 h to precipitate proteins, and pellet the proteins by centrifugation at 14,000 RPM for 20 min at 4 . 5. Decant supernatant, and dry pellet briefly in the air with the cap open. 6. Redissolve pellet in 30 ml of 25 mM Tris-HCl, pH 7.5, 25 mM NaCl, 2 mM DTT and 10% glycerol. 7. Separate apo-and holo-ACPs from the reactions by HPLC with a Jupiter C-18 column (5 mm, 300 Å , 250 Â 4.6 mm, Phenomenex), and a gradient elution from 85% buffer A (H 2 O þ 0.1% formic acid) to 90% buffer B (acetonitrile þ 0.1% formic acid) in 25 min at a flow rate of 1 ml/min, with UV detection at 220 nm (Fig. 8.6B ). Individual protein peaks are collected, lyophilized, and redissolved in 50 ml of H 2 O. 8. Determine the apo-and holo-ACPs by ESI-MS analysis in positive ionization mode on an Agilent 1000 HPLC-MSD SL instrument under standard operational conditions (Table 8 .2). 9. Scale up the reaction volume three-to five-fold for preparative reactions, and aliquot and store the holo-ACP samples from
Step 6 at -80 until use.
Heterologous expression and overproduction of discrete ATs
1. The majority of genes encoding discrete ATs for AT-less type I PKSs encode a single AT domain, but a few are predicted to encode tandem AT domains (see Table 8 .1). For those that encode a single AT domain, use the entire open reading frame for heterologous expression. For those that encode tandem AT domains, conduct sequence analysis [e.g., by ClustalW program (Thompson et al., 2002) ] to determine the boundaries of individual AT domains for heterologous expression, taking as much advantage as possible of their natural N-or C-terminus (Donadio and Katz, 1992) . 2. Follow Steps 2 through 8 as described in Section 2.1, but replace the target genes with those encoding discrete ATs. 3. Dialyze pooled protein samples against 25 mM Tris-HCl, pH 7.0, 25 mM NaCl, 2 mM DTT and 10% glycerol. 4. Re-examine the quality of the purified ATs by SDS-PAGE (Fig. 8.6C) , and determine their concentrations by Bradford assay (Bradford, 1976) . 5. Aliquot (e.g., 500 ml per 1.5-ml tube) and store the AT samples at -80 until use.
In vitro assay for AT substrate specificity
The protocol for a quasi-kinetic assay of AT substrate specificity was modified from previously published procedures (Liou et al., 2003; Szafranska et al., 2002) . Acyl CoAs (use 14 C-labeled acyl CoAs only for Type I Polyketide Synthases that Require Discrete Acyltransferases Table 8 .2 ESI-MS analysis of apo-, holo-, and malonyl-S-ACPs of the LnmI and LnmJ PKSs a The numbers after ACPs refer to the LNM PKS modules from which they are derived, with 6-1 and 6-2 to indicate the first and second ACPs, respectively, for LNM PKS module 6. autoradiography analysis) used include malonyl CoA, methylmalonyl CoA, butyryl CoA, propionyl CoA, and acetyl CoA.
1. Set up a typical in vitro AT self-acylation reaction in a 200-ml volume for each acyl CoA as follows: (1) 100 ml of 2 X reaction buffer (100 mM phosphate buffer, pH 7.0, 0.4 mM DTT, 0.2 mM EDTA); (2) 10 ml of acyl CoA and (final acyl CoA concentration 20 mM and $8 Â 10 8 DPM if 14 C-labeled acyl CoA is included); (3) 5 ml of LnmG (final concentration 2 mM and add in Step 3 to initiate reaction); and (4) add H 2 O to a total reaction volume of 200 ml 2. Equilibrate all reagents on ice (0 ) for 15 min or longer, and perform assay on ice to slow down the reaction. 3. Initiate reaction by adding LnmG and quickly mix by pipetting up and down several times. 4. Transfer 25 ml of reaction mixture to a tube containing 50 ml of ice-cold 10% TCA at each of the seven time points: 0.5, 1, 2, 4, 8, 16 and 32 min. 5. Add 25 ml of 10-mg/ml BSA to each tube as a carrier protein and allow proteins to precipitate on ice for 15 min. 6. Pellet proteins by centrifugation at 14,000 RPM for 20 min at 4 . 7. Wash protein pellet twice with 100 ml of 10% ice-cold TCA. 8. Solubilize the pellet in 100 ml of 10 mM NaCl, 2% SDS solution at ambient temperature. 9. Mix with 5 ml of scintillation cocktail and count radioactivity in a scintillation counter (Beckman Coulter). 10. Plot the radioactivity counts as a function of time for each acyl CoA.
Use the count of a 25-ml fraction directly from the original reaction (Step 4) as 100% DPM value. Normalize the 100% DPM values of individual acyl CoAs to that of malonyl CoA (Fig. 8.7A ). 11. Similarly, assays can be performed with a fixed amount of AT enzyme (2 mM of LnmG) and variable concentrations of acyl CoA in 25-ml reaction for 2 min on ice (Fig. 8.7B ).
In vitro assay of AT-catalyzed loading of acyl CoA extender substrate to holo-ACPs
This assay can be carried out in two completely separate steps (continuing from the holo-ACPs prepared from Step 9, Section 2.2) or in two consecutive steps in a single tube (continuing from the holo-ACPs prepared from
Step 2, Section 2.2). The protocol described below was modified from Lambalot et al. (1996) and Sanchez et al. (2001) and was developed for a typical analytical reaction. The loading of the acyl group from the acyl CoA substrate (malonyl CoA in the current example) onto holo-ACP can be followed by HPLC, MS or autoradiography analysis. Only the protocol for assay in a single tube is provided, which could be readily adapted for assay in Type I Polyketide Synthases that Require Discrete Acyltransferases two separate steps. For preparative reactions, scale up reaction volumes three-to five-fold.
1. Add to the reaction tube from the Step 2 of Section 2.2 a 25-ml solution containing 2 mM LnmG and 200 mM [2-14 C] malonyl CoA ($5 Â 10 8 DPM). 2a. For assaying one ACP in a time-course (Fig. 8.8A ), incubate the reactions at 25 and quench the reactions by adding 900 ml of acetone at various time points (1, 2, 4, 8, 16, 32, 64, and 128 min) . Mix briefly by vortexing. 2b. For assaying multiple ACPs at a fixed time point (Fig. 8.8B ), incubate the reactions at 25 and quench by adding 900 ml of acetone at a fixed time point (2 min). Mix briefly by vortexing. 5. Follow Steps 6 to 8 of Section 2.2 to analyze the resultant acyl-S-ACPs by HPLC (Fig. 8.6B ) and ESI-MS (Table 8 .2). 6. Alternatively, redissolve protein pellets in 25 ml of 1Â sampler buffer. 7. Analyze protein samples on a 4 to 15% SDS-PAGE gel (Bio-Rad), visualize proteins by Coomassie blue staining and record the gel image ( Fig. 8.8 ). 8. Air dry the gel and expose it to a low-energy (LE) phosphor screen (Amersham Pharmacia) at ambient temperature for 3 to 7 days to acquire autoradiography with a phosphorimager (Molecular Dynamics) (Fig. 8.8 ).
Conclusion
Bioinformatics analysis of gene clusters continues to unveil candidates encoding AT-less type I PKSs for natural product biosynthesis (Fig. 8.3 and Table 8 .1). The LNM PKS, however, remains the only AT-less type I PKS that has been confirmed experimentally, with LnmG acting in trans as a discrete AT responsible for loading the extender substrate malonyl CoA to all six modules of the LnmI and LnmJ PKS proteins (Cheng et al., 2003) . A significant knowledge gap exists between the predicted and experimentally validated involvement of AT-less type I PKSs in natural product biosynthesis, yet such information is absolutely required to realize the full potential of this subclass of novel PKSs in combinatorial biosynthesis for natural product structural diversity. It is hoped that methods devised for studies of the LNM PKS will be applicable to other AT-less type I PKSs, thereby aiding their biochemical and mechanistic characterization. Although gene expression in heterologous hosts such as E. coli is intrinsically unpredictable, overproduction of functional ACPs and discrete ATs generally does not constitute an insurmountable problem. ACPs overproduced in E. coli are often in the apo-form, but conversion to the functional holo-form is readily achievable thanks to the availability of promiscuous PPTases such as Svp (Sanchez et al., 2001) and Sfp (Lambalot et al., 1996) . While conceptually straightforward, care must be taken in executing assays for the substrate specificity of discrete ATs, since AT self-acylation reaction is often rapid and followed by a gradual spontaneous hydrolysis, and assays for discrete AT-catalyzed loading of extender substrates to holo-ACPs, because the general protocol often requires specific optimization, and acylated ACPs also undergo slow hydrolysis under the assay conditions (Fig. 8.5 ).
AT-less type I PKSs provide tremendous opportunities for PKS engineering. For instance, given that LnmG is responsible for the loading of the malonyl CoA extender unit to all six modules of the LnmI and LnmJ PKS, it was reasoned that LnmG could be a rate-limiting factor for LNM biosynthesis. Subsequent overexpression of lnmG under a strong promoter in the LNM-producing-strain S, atroolivaceus S-140 indeed resulted in improved LNM titers by three-to five-fold (Cheng et al., 2003; Tang et al., 2004) . It is also very tempting to envision the application of lnmG and other discrete AT-encoding genes to either prototypical type I PKSs or AT-less type I PKSs to alter the extender-unit specificity by combinatorial methods, thereby further expanding the size and diversity of polyketide natural products.
Finally, it is exciting to consider how these established methods designed with LNM in mind will also be applicable to decipher the mechanism by which AT-less type I PKSs accommodate multiple extender units. Take for instance the recently discovered discrete ATs from the etnangien biosynthetic pathway (EtnB) (Menche et al., 2008) , the kirromycin biosynthetic pathway (KirCII) (Weber et al., 2008) , and the oxazolomycin biosynthetic pathway (OzmC) (Zhao et al., 2009) , whose predicted substrate specificities are for succinyl CoA, ethylmalonyl CoA, and methoxymalonyl ACP, respectively, in addition to other dedicated discrete ATs for malonyl CoA in the same pathway. If experimentally proven, EtnB, KirCII, and OzmC, together with their corresponding AT-less PKS machinery, would provide additional opportunities to introduce uncommon extender units for engineering novel natural products by combinatorial biosynthesis methods.
